Vagus nerve stimulation

A. J. Rush, M. S. George, H. A. Sackeim, L. B. Marangell, M. M. Husain, Z. Nahas, T. Burt, C. R. Johnson

Research output: Contribution to journalArticle

Abstract

VNS, as delivered by the NCP system, is an FDA-approved, well-tolerated, effective intervention for a substantial proportion of patients with treatment-resistant epilepsy. Its longer term safety and tolerability are well documented in these patients. There are several clinical and theoretical reasons to think that VNS might be an effective antidepressant or mood stabilizer. A recent open, uncontrolled trial provided encouraging results. Most patients who responded acutely have maintained the benefits. Some subjects responded after exiting the acute study, while continuing to receive VNS in an uncontrolled follow-up. These results are similar to the increasing benefits with VNS over the longer term observed in patients with epilepsy. Major questions ranging from the need to establish efficacy in a controlled, comparative trial; determining indicators of who will respond; documentation of long-term efficacy; studies of cost recovery; and where VNS fits into the overall disease management scheme for depression deserve careful study.

Original languageEnglish (US)
Pages (from-to)55-87
Number of pages33
JournalPsychiatric Clinics of North America: Annual of Drug Therapy
StatePublished - 2001

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Disease Management
Documentation
Antidepressive Agents
Depression
Safety
Costs and Cost Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Rush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Nahas, Z., ... Johnson, C. R. (2001). Vagus nerve stimulation. Psychiatric Clinics of North America: Annual of Drug Therapy, 55-87.

Vagus nerve stimulation. / Rush, A. J.; George, M. S.; Sackeim, H. A.; Marangell, L. B.; Husain, M. M.; Nahas, Z.; Burt, T.; Johnson, C. R.

In: Psychiatric Clinics of North America: Annual of Drug Therapy, 2001, p. 55-87.

Research output: Contribution to journalArticle

Rush, AJ, George, MS, Sackeim, HA, Marangell, LB, Husain, MM, Nahas, Z, Burt, T & Johnson, CR 2001, 'Vagus nerve stimulation', Psychiatric Clinics of North America: Annual of Drug Therapy, pp. 55-87.
Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Nahas Z et al. Vagus nerve stimulation. Psychiatric Clinics of North America: Annual of Drug Therapy. 2001;55-87.
Rush, A. J. ; George, M. S. ; Sackeim, H. A. ; Marangell, L. B. ; Husain, M. M. ; Nahas, Z. ; Burt, T. ; Johnson, C. R. / Vagus nerve stimulation. In: Psychiatric Clinics of North America: Annual of Drug Therapy. 2001 ; pp. 55-87.
@article{33cbf15076d7436b90434fe018d6a5da,
title = "Vagus nerve stimulation",
abstract = "VNS, as delivered by the NCP system, is an FDA-approved, well-tolerated, effective intervention for a substantial proportion of patients with treatment-resistant epilepsy. Its longer term safety and tolerability are well documented in these patients. There are several clinical and theoretical reasons to think that VNS might be an effective antidepressant or mood stabilizer. A recent open, uncontrolled trial provided encouraging results. Most patients who responded acutely have maintained the benefits. Some subjects responded after exiting the acute study, while continuing to receive VNS in an uncontrolled follow-up. These results are similar to the increasing benefits with VNS over the longer term observed in patients with epilepsy. Major questions ranging from the need to establish efficacy in a controlled, comparative trial; determining indicators of who will respond; documentation of long-term efficacy; studies of cost recovery; and where VNS fits into the overall disease management scheme for depression deserve careful study.",
author = "Rush, {A. J.} and George, {M. S.} and Sackeim, {H. A.} and Marangell, {L. B.} and Husain, {M. M.} and Z. Nahas and T. Burt and Johnson, {C. R.}",
year = "2001",
language = "English (US)",
pages = "55--87",
journal = "Psychiatric Clinics of North America: Annual of Drug Therapy",
issn = "1068-3178",

}

TY - JOUR

T1 - Vagus nerve stimulation

AU - Rush, A. J.

AU - George, M. S.

AU - Sackeim, H. A.

AU - Marangell, L. B.

AU - Husain, M. M.

AU - Nahas, Z.

AU - Burt, T.

AU - Johnson, C. R.

PY - 2001

Y1 - 2001

N2 - VNS, as delivered by the NCP system, is an FDA-approved, well-tolerated, effective intervention for a substantial proportion of patients with treatment-resistant epilepsy. Its longer term safety and tolerability are well documented in these patients. There are several clinical and theoretical reasons to think that VNS might be an effective antidepressant or mood stabilizer. A recent open, uncontrolled trial provided encouraging results. Most patients who responded acutely have maintained the benefits. Some subjects responded after exiting the acute study, while continuing to receive VNS in an uncontrolled follow-up. These results are similar to the increasing benefits with VNS over the longer term observed in patients with epilepsy. Major questions ranging from the need to establish efficacy in a controlled, comparative trial; determining indicators of who will respond; documentation of long-term efficacy; studies of cost recovery; and where VNS fits into the overall disease management scheme for depression deserve careful study.

AB - VNS, as delivered by the NCP system, is an FDA-approved, well-tolerated, effective intervention for a substantial proportion of patients with treatment-resistant epilepsy. Its longer term safety and tolerability are well documented in these patients. There are several clinical and theoretical reasons to think that VNS might be an effective antidepressant or mood stabilizer. A recent open, uncontrolled trial provided encouraging results. Most patients who responded acutely have maintained the benefits. Some subjects responded after exiting the acute study, while continuing to receive VNS in an uncontrolled follow-up. These results are similar to the increasing benefits with VNS over the longer term observed in patients with epilepsy. Major questions ranging from the need to establish efficacy in a controlled, comparative trial; determining indicators of who will respond; documentation of long-term efficacy; studies of cost recovery; and where VNS fits into the overall disease management scheme for depression deserve careful study.

UR - http://www.scopus.com/inward/record.url?scp=0035204404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035204404&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035204404

SP - 55

EP - 87

JO - Psychiatric Clinics of North America: Annual of Drug Therapy

JF - Psychiatric Clinics of North America: Annual of Drug Therapy

SN - 1068-3178

ER -